Assessment of Synthesis Machinery of Two Antimicrobial Peptides from Paenibacillus alvei NP75
- PMID: 31001787
- DOI: 10.1007/s12602-019-09541-w
Assessment of Synthesis Machinery of Two Antimicrobial Peptides from Paenibacillus alvei NP75
Abstract
Paenibacillus alvei NP75, a Gram-positive bacterium, produces two different antimicrobial peptides, paenibacillin N and P, which has potent antimicrobial activity against many clinical pathogens. The synthesis pattern of these antimicrobial peptides by P. alvei NP75 was studied extensively. The results were outstanding in a way that the paenibacillin N was synthesized irrespective of the growth of bacteria (non-ribosomal mediated), whereas paenibacillin P production was carried out by ribosomal mediated. In addition to the antimicrobial peptides, P. alvei NP75 also produces an immunogenic extracellular protease to defend itself from its own antimicrobial peptide, paenibacillin P. Furthermore, this immunogenic protease production was impaired by the addition of protease inhibitor, phenylmethylsulfonyl fluoride (PMSF). The sodium dodecyl sulfate (SDS) treated strain (mutant) failed to produce paenibacillin P, whereas the production of neither paenibacillin N nor the protease was affected by the plasmid curing. The plasmid curing studies that divulge the genes responsible for the synthesis of paenibacillin N and protease were found to be genome encoded, and paenibacillin P was plasmid encoded. We are reporting, first of its kind, the co-production of two different antimicrobial peptides from P. alvei NP75 through non-ribosomal and ribosomal pathways that could be used as effective antibiotics.
Keywords: Antimicrobial peptides; Co-production; Non-ribosomal; Paenibacillus alvei; Plasmid encoded; Ribosomal.
Similar articles
-
Co-production of two new peptide antibiotics by a bacterial isolate Paenibacillus alvei NP75.Biochem Biophys Res Commun. 2009 Feb 6;379(2):179-85. doi: 10.1016/j.bbrc.2008.12.007. Epub 2008 Dec 13. Biochem Biophys Res Commun. 2009. PMID: 19073145
-
Biosynthesis of paenibacillin, a lantibiotic with N-terminal acetylation, by Paenibacillus polymyxa.Microbiol Res. 2015 Dec;181:15-21. doi: 10.1016/j.micres.2015.08.001. Epub 2015 Aug 7. Microbiol Res. 2015. PMID: 26640048
-
In-vitro studies on a natural lantibiotic, paenibacillin: A new-generation antibacterial drug candidate to overcome multi-drug resistance.Int J Antimicrob Agents. 2019 Jun;53(6):838-843. doi: 10.1016/j.ijantimicag.2019.03.020. Epub 2019 Mar 28. Int J Antimicrob Agents. 2019. PMID: 30928682
-
Bacillus and Paenibacillus secreted polyketides and peptides involved in controlling human and plant pathogens.Appl Microbiol Biotechnol. 2019 Feb;103(3):1189-1215. doi: 10.1007/s00253-018-9541-0. Epub 2019 Jan 3. Appl Microbiol Biotechnol. 2019. PMID: 30603850 Review.
-
Overview of ribosomal and non-ribosomal antimicrobial peptides produced by Gram positive bacteria.Cell Mol Biol (Noisy-le-grand). 2017 Oct 31;63(10):20-32. doi: 10.14715/cmb/2017.63.10.4. Cell Mol Biol (Noisy-le-grand). 2017. PMID: 29096754 Review.
Cited by
-
Differential impact of Paenibacillus infection on the microbiota of Varroa destructor and Apis mellifera.Heliyon. 2024 Oct 16;10(22):e39384. doi: 10.1016/j.heliyon.2024.e39384. eCollection 2024 Nov 30. Heliyon. 2024. PMID: 39624306 Free PMC article.
-
Combinatorial approach for screening and assessment of multiple therapeutic enzymes from marine isolate Pseudomonas aeruginosa AR01.RSC Adv. 2019 May 31;9(30):16989-17001. doi: 10.1039/c9ra02555c. eCollection 2019 May 29. RSC Adv. 2019. PMID: 35519884 Free PMC article.
-
Paenibacillus alvei MP1 as a Producer of the Proteinaceous Compound with Activity against Important Human Pathogens, Including Staphylococcus aureus and Listeria monocytogenes.Pathogens. 2020 Apr 25;9(5):319. doi: 10.3390/pathogens9050319. Pathogens. 2020. PMID: 32344843 Free PMC article.
References
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources